Cargando…

Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI

BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimek, Ludger, Bergmann, Karl-Christian, Brehler, Randolf, Pfützner, Wolfgang, Zuberbier, Torsten, Hartmann, Karin, Jakob, Thilo, Novak, Natalija, Ring, Johannes, Merk, Hans, Hamelmann, Eckard, Ankermann, Tobias, Schmidt, Sebastian, Untersmayr, Eva, Hötzenecker, Wolfram, Jensen-Jarolim, Erika, Brockow, Knut, Mahler, Vera, Worm, Margitta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054127/
https://www.ncbi.nlm.nih.gov/pubmed/33898162
http://dx.doi.org/10.1007/s40629-021-00165-7
_version_ 1783680243546980352
author Klimek, Ludger
Bergmann, Karl-Christian
Brehler, Randolf
Pfützner, Wolfgang
Zuberbier, Torsten
Hartmann, Karin
Jakob, Thilo
Novak, Natalija
Ring, Johannes
Merk, Hans
Hamelmann, Eckard
Ankermann, Tobias
Schmidt, Sebastian
Untersmayr, Eva
Hötzenecker, Wolfram
Jensen-Jarolim, Erika
Brockow, Knut
Mahler, Vera
Worm, Margitta
author_facet Klimek, Ludger
Bergmann, Karl-Christian
Brehler, Randolf
Pfützner, Wolfgang
Zuberbier, Torsten
Hartmann, Karin
Jakob, Thilo
Novak, Natalija
Ring, Johannes
Merk, Hans
Hamelmann, Eckard
Ankermann, Tobias
Schmidt, Sebastian
Untersmayr, Eva
Hötzenecker, Wolfram
Jensen-Jarolim, Erika
Brockow, Knut
Mahler, Vera
Worm, Margitta
author_sort Klimek, Ludger
collection PubMed
description BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. METHODS: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). RESULTS: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. CONCLUSION: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose.
format Online
Article
Text
id pubmed-8054127
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-80541272021-04-19 Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI Klimek, Ludger Bergmann, Karl-Christian Brehler, Randolf Pfützner, Wolfgang Zuberbier, Torsten Hartmann, Karin Jakob, Thilo Novak, Natalija Ring, Johannes Merk, Hans Hamelmann, Eckard Ankermann, Tobias Schmidt, Sebastian Untersmayr, Eva Hötzenecker, Wolfram Jensen-Jarolim, Erika Brockow, Knut Mahler, Vera Worm, Margitta Allergo J Int Position Article BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. METHODS: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). RESULTS: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. CONCLUSION: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose. Springer Medizin 2021-04-19 2021 /pmc/articles/PMC8054127/ /pubmed/33898162 http://dx.doi.org/10.1007/s40629-021-00165-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Position Article
Klimek, Ludger
Bergmann, Karl-Christian
Brehler, Randolf
Pfützner, Wolfgang
Zuberbier, Torsten
Hartmann, Karin
Jakob, Thilo
Novak, Natalija
Ring, Johannes
Merk, Hans
Hamelmann, Eckard
Ankermann, Tobias
Schmidt, Sebastian
Untersmayr, Eva
Hötzenecker, Wolfram
Jensen-Jarolim, Erika
Brockow, Knut
Mahler, Vera
Worm, Margitta
Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
title Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
title_full Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
title_fullStr Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
title_full_unstemmed Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
title_short Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
title_sort practical handling of allergic reactions to covid-19 vaccines: a position paper from german and austrian allergy societies aeda, dgaki, gpa and ögai
topic Position Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054127/
https://www.ncbi.nlm.nih.gov/pubmed/33898162
http://dx.doi.org/10.1007/s40629-021-00165-7
work_keys_str_mv AT klimekludger practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT bergmannkarlchristian practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT brehlerrandolf practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT pfutznerwolfgang practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT zuberbiertorsten practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT hartmannkarin practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT jakobthilo practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT novaknatalija practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT ringjohannes practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT merkhans practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT hamelmanneckard practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT ankermanntobias practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT schmidtsebastian practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT untersmayreva practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT hotzeneckerwolfram practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT jensenjarolimerika practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT brockowknut practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT mahlervera practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai
AT wormmargitta practicalhandlingofallergicreactionstocovid19vaccinesapositionpaperfromgermanandaustrianallergysocietiesaedadgakigpaandogai